Bedford, Massachusetts-based biopharmaceutical company Ocular Therapeutix, Inc. has made significant strides in its focus on the formulation, development, and commercialization of therapies for various diseases and conditions of the eye in the United States. Utilizing its proprietary bioresorbable hydrogel-based formulation technology, the company has marketed two products: ReSure Sealant, an ophthalmic device that prevents wound leaks in corneal incisions following cataract surgery, and DEXTENZA, a dexamethasone ophthalmic insert for treating post-surgical ocular inflammation, pain following ophthalmic surgery, and allergic conjunctivitis. Ocular Therapeutix is also in the process of developing several other treatment options, including OTX-TKI, an axitinib intravitreal implant that's currently in phase 1 clinical trials for the treatment of retinal diseases; OTX-TIC, a travoprost intracameral implant in phase 2 clinical trials for the treatment of open-angle glaucoma and ocular hypertension; and OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for dry eye disease. In addition, the company is conducting phase 2 clinical trials for its OTX-DED dexamethasone intracanalicular insert, which aims to provide short-term treatment for the signs and symptoms of dry eye disease. Ocular Therapeutix has also entered strategic collaborations to further expand its reach. These collaborations include a partnership with Regeneron Pharmaceuticals, Inc. to develop and commercialize products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases. The company has also teamed up with AffaMed Therapeutics Limited to develop and commercialize DEXTENZA and OTX-TIC, and has recently formed a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration. Founded in 2006, Ocular Therapeutix, Inc. is committed to advancing innovative treatment options for diseases and conditions of the eye.
Ocular Therapeutix's ticker is OCUL
The company's shares trade on the NASDAQ stock exchange
They are based in Bedford, Massachusetts
There are 51-200 employees working at Ocular Therapeutix
It is ocutx.com/about/company
Ocular Therapeutix is in the Healthcare sector
Ocular Therapeutix is in the Biotechnology industry
The following five companies are Ocular Therapeutix's industry peers: